Duke professor's research leads to first drug for type of liver disease - The Chronicle
The FDA approved resmetirom, a drug for metabolic dysfunction-associated steatohepatitis (MASH), developed by Duke professor Paul Yen. Resmetirom targets MASH, a liver disease linked to obesity, affecting 115 million globally. Yen's research, focusing on thyroid hormones, led to the drug's development, aiming to prevent severe complications like cirrhosis and cardiovascular disease.
Reference News
The FDA approved resmetirom, a drug for metabolic dysfunction-associated steatohepatitis (MASH), developed by Duke professor Paul Yen. Resmetirom targets MASH, a liver disease linked to obesity, affecting 115 million globally. Yen's research, focusing on thyroid hormones, led to the drug's development, aiming to prevent severe complications like cirrhosis and cardiovascular disease.